ReviewFrontiers in pharmacology2026
Application of the miRNAs as biomarkers and therapeutic strategies in periodontal inflammation.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MicroRNAs in periodontal disease: from pathogenic mechanisms and RANKL/OPG regulation to nanoparticle delivery and personalized medicine.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory and host immunological responses to bacterial tooth infections contribute to the development of periodontal disease. MiRNAs (miRNAs) play a critical role in regulating these immunological and inflammatory responses. miRNAs influence both innate and adaptive immunity in periodontal disease, affecting the functions of T and B cells, neutrophils, macrophages, and dendritic cells. This review examines the regulatory roles of miRNAs in periodontal tissues and evaluates their potential as therapeutic agents and biomarkers. Upregulated miRNAs identified include miR-146a, miR-29, miR-15, miR-148, and miR-223, while miR-31, miR-92, and miR-451 are downregulated. The review emphasizes the altered expression of miRNAs in periodontitis models. Selective targeting of miRNA pathways, enabled by gain or loss-of-function approaches, represents a promising strategy for therapeutic intervention. Additionally, the stability of miRNAs in gingival crevicular fluid and their association with specific features of periodontal disease underscore their potential as indicators of disease progression or tissue recovery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.